ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First Patient Dosed with the Affinity-Tailored T-Cell-adaptor in Phase I Study
August 01, 2019GEMoaB GmbH announced the dosing of the first patient in a Phase I open-label, dose escalation study of GEM3PSCA, an Affinity-Tailored Adapter for T-Cells (ATAC). The bispecific antibody binds to the CD3-Receptor on T-cells and prostate stem cell antigen
Pharma Sources Insight January 2025
